that's what the excitement of veeva is about.arter with had what i call a 30/30 quarter with more than 30% growth and 30% profit. that's by having a lot of products we can sell to customers and being their strategic partner and thinking about it long term. that's veeva in a nutshell there. >> we had a lot of biotechs on and you said you worked with some of the bio-techs. if they're starting new, it's right to go with veeva than the old way, right? >> absolutely. when they're first commercializing their products going to market, they often get a whole suite of software, they don't have to mess around with the old legacy systems and especially in the biotechs, speed is what they need. they develop those products, get those patents and get the regulatory approval and need to bring it to market. they don't need a fuss of it things getting in their way. >> we know president trump wants to streamline things and make it so there's not as much regulation? is this something if i were a share holder of veeva, where we're meeting these stan